12:00 AM
Jul 16, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Elelyso taliglucerase alfa: Phase IV data

The double-blind, international Phase IV PB-06-005 trial in 11 treatment-naïve pediatric patients showed that 30 and 60 U/kg Elelyso increased mean hemoglobin concentration, the primary endpoint, from baseline at month 12 by 13.8% and 15.8%, respectively. In anemic patients (n=7), Elelyso increased mean hemoglobin concentration from baseline at month 12 by 4.3 g/dL for the 30 U/kg dose and by 1.7...

Read the full 282 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >